I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.11 SGD -1.79% Market Closed
Market Cap: 105.2m SGD

Profitability Summary

IX Biopharma Ltd's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
IX Biopharma Ltd

Revenue
7.8m SGD
Cost of Revenue
-5.7m SGD
Gross Profit
2m SGD
Operating Expenses
-8.1m SGD
Operating Income
-6.1m SGD
Other Expenses
-4.1m SGD
Net Income
-10.1m SGD

Margins Comparison
IX Biopharma Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
SG
IX Biopharma Ltd
SGX:42C
97.7m SGD
26%
-78%
-131%
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
83%
44%
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
68%
27%
27%
CH
Roche Holding AG
SIX:ROG
252.4B CHF
74%
34%
15%
UK
AstraZeneca PLC
LSE:AZN
209.5B GBP
82%
24%
16%
CH
Novartis AG
SIX:NOVN
203.3B CHF
76%
33%
26%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
79%
38%
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
82%
42%
33%
IE
Endo International PLC
LSE:0Y5F
206B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
146.7B USD
75%
29%
16%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
IX Biopharma Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
SG
IX Biopharma Ltd
SGX:42C
97.7m SGD
-431%
-78%
-127%
-82%
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
97%
19%
42%
25%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
33%
13%
18%
13%
CH
Roche Holding AG
SIX:ROG
252.4B CHF
33%
10%
31%
19%
UK
AstraZeneca PLC
LSE:AZN
209.5B GBP
22%
9%
18%
15%
CH
Novartis AG
SIX:NOVN
203.3B CHF
33%
14%
25%
18%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
40%
15%
26%
21%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
71%
23%
57%
28%
IE
Endo International PLC
LSE:0Y5F
206B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
146.7B USD
11%
5%
11%
10%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less